(Q34819051)

4 August 2017

1 reference

title

Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction (English)

1 reference

4 August 2017

0 references

1 reference

Roger K Verbeeck

1

1 reference

4 August 2017

publication date

2 September 2008

1 reference

European Journal of Clinical Pharmacology

4 August 2017

published in

1 reference

4 August 2017

volume

64

1 reference

4 August 2017

issue

12

1 reference

4 August 2017

page(s)

1147-1161

1 reference

https://scigraph.springernature.com/pub.10.1007/s00228-008-0553-z

4 August 2017

exact match

0 references

cites work

Pharmacokinetics of midazolam following intravenous and oral administration in patients with chronic liver disease and in healthy subjects.

1 reference

https://api.crossref.org/works/10.1007%2FS00228-008-0553-Z

The metabolism and bioavailability of morphine in patients with severe liver cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-008-0553-Z

Nifedipine: kinetics and hemodynamic effects in patients with liver cirrhosis after intravenous and oral administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-008-0553-Z

Biological determinants of propranolol disposition in normal subjects and patients with cirrhosis [proceedings]

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-008-0553-Z

Pharmacokinetics, bioavailability and ECG response of verapamil in patients with liver cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-008-0553-Z

Protein Binding and Kinetics of Drugs in Liver Diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-008-0553-Z

Normal disposition of oxazepam in acute viral hepatitis and cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-008-0553-Z

Effects of aging and liver disease on disposition of lorazepam

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-008-0553-Z

Disposition of diazepam and its major metabolite desmethyldiazepam in patients with liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-008-0553-Z

Extrahepatic metabolism of morphine occurs in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-008-0553-Z

Pharmacokinetics of zidovudine in patients with liver cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-008-0553-Z

Pharmacokinetics of oral mycophenolate mofetil in volunteer subjects with varying degrees of hepatic oxidative impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-008-0553-Z

Penetration of clindamycin phosphate into the abnormal human biliary tract

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-008-0553-Z

Alterations in isoprenaline sensitivity in patients with cirrhosis: evidence of abnormality of the sympathetic nervous activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-008-0553-Z

The pharmacokinetics and pharmacodynamics of the diuretic bumetanide in hepatic and renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-008-0553-Z

Stereoselective pharmacokinetics of oral and intravenous nitrendipine in healthy male subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-008-0553-Z

Disposition of a flow-limited drug (lidocaine) and a metabolic capacity-limited drug (theophylline) in liver cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-008-0553-Z

Cholestasis and endogenous opioids: liver disease and exogenous opioid pharmacokinetics

21 January 2018

1 reference

12 December 2020

Therapeutic implications of impaired hepatic oxygen diffusion in chronic liver disease

1 reference

12 December 2020

Plasma disappearance rate of indocyanine green in liver dysfunction.

1 reference

12 December 2020

Triamterene kinetics and dynamics in cirrhosis

1 reference

12 December 2020

Steady-state extrarenal sorbitol clearance as a measure of hepatic plasma flow

1 reference

12 December 2020

Pharmacokinetics of chlormethiazole in healthy volunteers and patients with cirrhosis of the liver

1 reference

12 December 2020

Prognostic value of the aminopyrine breath test in cirrhotic patients

1 reference

12 December 2020

Pharmacokinetics of Temafloxacin in Patients with Liver Impairment†

1 reference

12 December 2020

Nisoldipine: kinetics and effects on blood pressure and heart rate in patients with liver cirrhosis after intravenous and oral administration

1 reference

12 December 2020

Effects of liver disease on pharmacokinetics. An update

1 reference

12 December 2020

Cephalexin Levels in Human Bile in Presence of Biliary Tract Disease

1 reference

12 December 2020

An evaluation of the suitability of intravenous midazolam as an in vivo marker for hepatic cytochrome P4503A activity

1 reference

12 December 2020

Antiretroviral therapy : pharmacokinetic considerations in patients with renal or hepatic impairment

1 reference

12 December 2020

The complexities of hepatic drug transport: current knowledge and emerging concepts.

1 reference

12 December 2020

Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism

1 reference

12 December 2020

Antipyrine as a probe for human oxidative drug metabolism: Identification of the cytochrome P450 enzymes catalyzing 4-hydroxyantipyrine, 3-hydroxymethylantipyrine, and norantipyrine formation*

1 reference

12 December 2020

Furosemide kinetics and dynamics in patients with cirrhosis

1 reference

12 December 2020

Mdr1 limits CYP3A metabolism in vivo.

1 reference

12 December 2020

Cimetidine disposition in patients with Laennec's cirrhosis during multiple dosing therapy

1 reference

12 December 2020

The erythromycin breath test for the prediction of drug clearance

1 reference

12 December 2020

Hepatic and intestinal cytochrome P450 3A activity in cirrhosis: effects of transjugular intrahepatic portosystemic shunts

1 reference

12 December 2020

The Role of the Sinusoidal Endothelium in Liver Function

1 reference

12 December 2020

Adaptive changes in hepatobiliary transporter expression in primary biliary cirrhosis.

1 reference

12 December 2020

Biliary excretion of ceftriaxone into non-stagnant and stagnant bile

1 reference

12 December 2020

Pharmacokinetics of levetiracetam in patients with moderate to severe liver cirrhosis (Child-Pugh classes A, B, and C): characterization by dynamic liver function tests

1 reference

12 December 2020

In vitro and in vivo correlation of hepatic transporter effects on erythromycin metabolism: characterizing the importance of transporter-enzyme interplay

1 reference

12 December 2020

Biliary excretion of ciprofloxacin and piperacillin in the obstructed biliary tract

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of torasemide and furosemide in patients with diuretic resistant ascites

1 reference

12 December 2020

Influence of hepatic impairment on everolimus pharmacokinetics: implications for dose adjustment

1 reference

12 December 2020

Hepatic extraction of morphine is impaired in cirrhosis

1 reference

12 December 2020

Kinetics and dynamics of triamterene at steady-state in patients with cirrhosis

1 reference

12 December 2020

Localization of uridine 5'-diphosphate-glucuronosyltransferase in human liver injury

1 reference

12 December 2020

The hepatic sinusoid in aging and cirrhosis: effects on hepatic substrate disposition and drug clearance.

1 reference

12 December 2020

Liver disease selectively modulates cytochrome P450--mediated metabolism

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of intravenous midazolam in patients with severe alcoholic cirrhosis

1 reference

12 December 2020

Unpredictability of clinical evaluation of renal function in cirrhosis. Prospective study

1 reference

12 December 2020

Ranitidine disposition and systemic availability in hepatic cirrhosis

1 reference

12 December 2020

The effect of liver cirrhosis on the regulation and expression of drug metabolizing enzymes.

1 reference

12 December 2020

Pharmacotherapy of ascites associated with cirrhosis

1 reference

12 December 2020

Cytochrome P450 1A2 is a major determinant of lidocaine metabolism in vivo: effects of liver function

1 reference

12 December 2020

Review article: breath testing for human liver function assessment

1 reference

12 December 2020

Differential alterations of cytochrome P450 proteins in livers from patients with severe chronic liver disease

1 reference

12 December 2020

Expression of the hepatocyte canalicular multidrug resistance protein (MRP2) in primary biliary cirrhosis

1 reference

12 December 2020

Gastrointestinal dysfunction in liver disease and portal hypertension. Gut-liver interactions revisited

1 reference

12 December 2020

Dose adjustment in patients with liver disease

1 reference

12 December 2020

Assessment of lidocaine metabolite formation in comparison with other quantitative liver function tests.

1 reference

12 December 2020

Is glucuronidation truly preserved in patients with liver disease?

1 reference

12 December 2020

The erythromycin breath test reflects P-glycoprotein function independently of cytochrome P450 3A activity

1 reference

12 December 2020

Influence of hepatic cirrhosis and end-stage renal disease on pharmacokinetics and pharmacodynamics of furosemide

1 reference

12 December 2020

Cytochrome P450 and liver diseases

1 reference

12 December 2020

Glucuronidation of drugs by hepatic microsomes derived from healthy and cirrhotic human livers

1 reference

12 December 2020

Antiarrhythmics: elimination and dosage considerations in hepatic impairment

1 reference

12 December 2020

The role of hepatic and extrahepatic UDP-glucuronosyltransferases in human drug metabolism

1 reference

12 December 2020

Enhanced bioavailability and decreased clearance of analgesics in patients with cirrhosis

1 reference

12 December 2020

Assessment of the hepatic circulation in humans: new concepts based on evidence derived from a D-sorbitol clearance method.

1 reference

12 December 2020

Identification of patients with impaired hepatic drug metabolism using a limited sampling procedure for estimation of phenazone (antipyrine) pharmacokinetic parameters.

1 reference

12 December 2020

Both phenolic and acyl glucuronidation pathways of diflunisal are impaired in liver cirrhosis

1 reference

12 December 2020

Mechanisms of bile formation, hepatic uptake, and biliary excretion.

1 reference

12 December 2020

Decreased first-pass metabolism of labetalol in chronic liver disease

1 reference

12 December 2020

Measuring lidocaine metabolite--monoethylglycinexylidide as a quantitative index of hepatic function in adults with chronic hepatitis and cirrhosis.

1 reference

12 December 2020

Hepatic clearance and liver blood flow

1 reference

12 December 2020

First-pass elimination. Basic concepts and clinical consequences

1 reference

12 December 2020

Glucuronidation of oxazepam is not spared in patients with hepatic encephalopathy

1 reference

12 December 2020

Integration of hepatic drug transporters and phase II metabolizing enzymes: mechanisms of hepatic excretion of sulfate, glucuronide, and glutathione metabolites

1 reference

12 December 2020

Dynamic tests to study liver function.

1 reference

12 December 2020

The MEGX test: a tool for the real-time assessment of hepatic function

1 reference

12 December 2020

Model for end-stage liver disease (MELD) and allocation of donor livers

1 reference

12 December 2020

Clearance approaches in pharmacology.

1 reference

12 December 2020

Transection of the oesophagus for bleeding oesophageal varices

1 reference

12 December 2020

Pharmacokinetics of cefodizime in patients with liver cirrhosis and ascites

1 reference

12 December 2020

Clearance concepts in pharmacokinetics

1 reference

12 December 2020

Evidence for down-regulation of beta-2-adrenoceptors in cirrhotic patients with severe ascites

1 reference

12 December 2020

Pharmacokinetics of furosemide in patients with hepatic cirrhosis

1 reference

12 December 2020

Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide in patients with cirrhosis

1 reference

12 December 2020

Hepatic First-pass Metabolism in Liver Disease

1 reference

12 December 2020

The effects of age and chronic liver disease on the elimination of temazepam

1 reference

12 December 2020

Influence of cirrhosis on lamotrigine pharmacokinetics

1 reference

12 December 2020

Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects

1 reference

12 December 2020

Naproxen disposition in patients with alcoholic cirrhosis

1 reference

12 December 2020

Direct evidence for the intact hepatocyte theory in patients with liver cirrhosis.

1 reference

12 December 2020

Cardiovascular drug therapy in patients with hepatic diseases and patients with congestive heart failure

1 reference

12 December 2020

Dosage adjustment for hepatic dysfunction based on Child-Pugh scores.

1 reference

12 December 2020

Individual variation in first-pass metabolism

1 reference

12 December 2020

Mechanism of the excessive sedative response of cirrhotics to benzodiazepines: model experiments with triazolam.

1 reference

12 December 2020

Pharmacokinetics of opioids in liver disease

1 reference

12 December 2020

Measured creatinine clearance from timed urine collections substantially overestimates glomerular filtration rate in patients with liver cirrhosis: a systematic review and individual patient meta-analysis

1 reference

12 December 2020

The effect of obstruction on the biliary excretion of cefoperazone and ceftazidime

1 reference

12 December 2020

Assessment of intestinal permeability and absorption in cirrhotic patients with ascites using combined sugar probes

1 reference

12 December 2020

A systematic review of the performance of the model for end-stage liver disease (MELD) in the setting of liver transplantation

1 reference

12 December 2020

Assessment of hepatic blood flow in healthy subjects by continuous infusion of indocyanine green

1 reference

12 December 2020

Selective effect of liver disease on the activities of specific metabolizing enzymes: investigation of cytochromes P450 2C19 and 2D6.

1 reference

12 December 2020

Disposition kinetics and concentration-effect relationship of metipranolol in patients with cirrhosis and healthy subjects.

1 reference

12 December 2020

Pharmacokinetics of Metoprolol in Patients with Hepatic Cirrhosis

1 reference

12 December 2020

Assessment of liver metabolic function. Clinical implications

1 reference

12 December 2020

Drug acetylation in liver disease

1 reference

12 December 2020

Plasma levels and urinary excretion of lormetazepam in patients with liver cirrhosis and in healthy volunteers

1 reference

12 December 2020

Drugs in liver disease

1 reference

12 December 2020

Significance of the minor cytochrome P450 3A isoforms.

1 reference

12 December 2020

Molecular regulation of hepatocellular transport systems in cholestasis

1 reference

12 December 2020

Pre-translational regulation of cytochrome P450 genes is responsible for disease-specific changes of individual P450 enzymes among patients with cirrhosis.

1 reference

12 December 2020

Increased brain concentrations of endogenous (non-benzodiazepine) GABA-A receptor ligands in human hepatic encephalopathy

1 reference

12 December 2020

The cytochrome P450 superfamily: biochemistry, evolution and drug metabolism in humans

1 reference

12 December 2020

Relationship among beta-adrenergic blockade, propranolol concentration, and liver function in patients with cirrhosis

1 reference

12 December 2020

Diagnostic value of plasma cystatin C as a glomerular filtration marker in decompensated liver cirrhosis

1 reference

12 December 2020

Limitations of serum creatinine level and creatinine clearance as filtration markers in cirrhosis

1 reference

12 December 2020

Ampicillin Levels in Human Bile in the Presence of Biliary Tract Disease

1 reference

12 December 2020

Dose adaptation of antineoplastic drugs in patients with liver disease

1 reference

12 December 2020

UDP glucuronosyltransferase mRNA levels in human liver disease

1 reference

12 December 2020

Failure of erythromycin breath test to correlate with midazolam clearance as a probe of cytochrome P4503A.

1 reference

12 December 2020

Clinical pharmacokinetic and pharmacodynamic considerations in patients with liver disease. An update

1 reference

12 December 2020

Caffeine: a model compound for measuring liver function.

1 reference

12 December 2020

Hepatobiliary transporter expression in percutaneous liver biopsies of patients with cholestatic liver diseases.

1 reference

12 December 2020

The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin.

1 reference

12 December 2020

10.1007/S00228-008-0553-Z

Identifiers

DOI

1 reference

Dimensions Publication ID

4 August 2017

1013600709

0 references

1 reference